MedPath

Optimizing propofol in obese patients

Phase 1
Conditions
Depth of anesthesia during hysterescomia in propofol/remifentanil anaesthesia
Registration Number
EUCTR2005-005400-17-DK
Lead Sponsor
Dept. of Anaesthesia, Center of Head and Orthopaedics, Copenhagen University Hospital Rigshospitalet
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Recruiting
Sex
Female
Target Recruitment
38
Inclusion Criteria

Elective abdominal non-laparoscopic hysterectomia
Age>18 years
ASA physical status I-III
Body Mass Index =30
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

Allergic towards propofol
Daily consumption of benzodiazepine (more than at nighttime), opioids or amphetamine preoperatively.
Disease with expected EEG-abnormality or impaired auditory function: Epilepsy, deafness, previous neurosurgery, previous or actual neurologic disease with neurologic deficit.

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Main Objective: To optimize propofol dosing in obese patients undergoing hysterectomia.<br><br>Main hypothesis: Monitoring the depth of anaesthesia using the Cerebral State MonitorTM (CSM) reduce time to opening eyes in obese patients after hysterectomia in propofol/remifentanil anaethesia.<br>;Secondary Objective: Secondary hypotheses: CSM-monitoring reduce propofol dose in obese patients undergoing hysterectomia. Patients with a high CSM-level CSM-niveau during hysterectomia have higher postoperative consumption of analgesics. Supplementary, an algoritm for the dose of propofol that most frequently results in a CSM-level between 40 og 60 is calculated.<br>;Primary end point(s): Time to opening eyes in obese patients after hysterectomia in propofol/remifentanil anaethesia with or without CSM-guidance.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath